Dexmedetomidine in IVRA

• Status: Completed
• Trial end date: 2021-06-20
• Target enrollment: 0
• Participant gender: All

Summary

A prospective randomized controlled double-blinded study will be conducted on 90 patients assigned randomly into three equal groups,

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Menoufia University
• Collaborators: Ayman Ahmed Radi; Mohamed Abodief Mohamed Ahmed; Sadik Abdel Maseeh Sadik
• Treatments: Dexmedetomidine; Lidocaine

Criteria

Inclusion Criteria:

1. Patients of ASA class I and II.

2. Patients of either sex.

3. Patients aged between 20-70 years.

4. Patients scheduled for forearm and hand surgery lasting for about 60 minutes.

Exclusion Criteria:

• 1. Patient with known hypersensitivity to any study medications. 2. Patient with Severe peripheral vascular disease and neurological disease. 3. Where use of tourniquet will be either not possible or contraindicated. 4. Patient with Hemolytic diathesis specially sickle cell anemia, epilepsy, diabetes mellitus, hypertension, cardiovascular disease like myocardial infarction, cardiac arrhythmias, heart block and altered mentation. 5. Procedures lasting for more than 90 min will be also not considered. 6. Therapy with adrenergic receptor antagonist, calcium channel blocker and ACE inhibitors. 7. Patient with impaired liver function.